{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T11:02:11Z","timestamp":1769598131645,"version":"3.49.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Electrocardiology"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.jelectrocard.2016.12.004","type":"journal-article","created":{"date-parts":[[2016,12,29]],"date-time":"2016-12-29T15:48:12Z","timestamp":1483026492000},"page":"294-300","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Does antiarrhythmic drugs premedication improve electrical cardioversion success in persistent atrial fibrillation?"],"prefix":"10.1016","volume":"50","author":[{"given":"Elisabetta","family":"Toso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0571-3918","authenticated-orcid":false,"given":"Mario","family":"Iannaccone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Caponi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Rotondi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Scaglione","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiorenzo","family":"Gaita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jelectrocard.2016.12.004_bb0005","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1136\/hrt.2002.008748","article-title":"Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK","volume":"90","author":"Stewart","year":"2004","journal-title":"Heart"},{"key":"10.1016\/j.jelectrocard.2016.12.004_bb0010","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1093\/eurheartj\/ehq278","article-title":"Guidelines for the management of atrial fibrillation: the task force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)","volume":"31","author":"Camm","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jelectrocard.2016.12.004_bb0015","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1056\/NEJMoa021328","article-title":"Atrial fibrillation follow-up investigation of rhythm management (AFFIRM) investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation","volume":"347","author":"Wyse","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jelectrocard.2016.12.004_bb0020","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1161\/01.CIR.0000121736.16643.11","article-title":"Relationships between sinus rhythm, treatment, and survival in the atrial fibrillation follow-up investigation of rhythm management (AFFIRM) study","volume":"109","author":"Corley","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jelectrocard.2016.12.004_bb0025","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1161\/CIRCULATIONAHA.112.092494","article-title":"Rhythm versus rate control therapy and subsequent stroke or transient ischemic attack in patients with atrial fibrillation","volume":"126","author":"Corley","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jelectrocard.2016.12.004_bb0030","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0735-1097(01)01540-6","article-title":"Initial energy setting, outcome and efficiency in direct current cardioversion of atrial fibrillation and flutter","volume":"38","author":"Gallagher","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jelectrocard.2016.12.004_bb0035","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1111\/j.1540-8159.2012.03453.x","article-title":"Electrical cardioversion of persistent atrial fibrillation: acute and long-term results stratified according to arrhythmia duration","volume":"35","author":"Toso","year":"2012","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1016\/j.jelectrocard.2016.12.004_bb0040","doi-asserted-by":"crossref","first-page":"147R","DOI":"10.1016\/S0002-9149(99)00715-8","article-title":"Pharmacologic versus direct-current electrical cardioversion of atrial flutter and fibrillation","volume":"84","author":"Van Gelder","year":"1999","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jelectrocard.2016.12.004_bb0045","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1111\/j.1540-8159.2007.00893.x","article-title":"Transthoracic versus transesophageal cardioversion of atrial fibrillation under light sedation: a prospective randomized trial","volume":"30","author":"Santini","year":"2007","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1016\/j.jelectrocard.2016.12.004_bb0050","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1093\/eurheartj\/ehs253","article-title":"2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association","volume":"33","author":"Camm","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jelectrocard.2016.12.004_bb0055","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1161\/01.CIR.84.4.1831","volume":"84","year":"1991","journal-title":"Circulation"},{"key":"10.1016\/j.jelectrocard.2016.12.004_bb0060","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/j.1742-1241.2007.01298.x","article-title":"Electrical cardioversion for persistent atrial fibrillation or atrial flutter in clinical practice: predictors of long-term outcome","volume":"61","author":"Boriani","year":"2007","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jelectrocard.2016.12.004_bb0065","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1056\/NEJM199906173402401","article-title":"Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment","volume":"340","author":"Elhendy","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jelectrocard.2016.12.004_bb0070","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/0002-9149(89)91090-4","article-title":"Effects of flecainide on the atrial fibrillation threshold","volume":"63","author":"Van Gelder","year":"1989","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jelectrocard.2016.12.004_bb0075","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ehj.2003.10.020","article-title":"A randomized placebo-controlled trial of pre-treatment and short- or long term maintenance therapy with amiodarone supporting DC cardioversion for persistent atrial fibrillation","volume":"25","author":"Channer","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jelectrocard.2016.12.004_bb0080","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1056\/NEJMoa041705","article-title":"For the sotalol amiodarone atrial fibrillation efficacy trial (SAFE-T) investigators* amiodarone versus sotalol for atrial fibrillation","volume":"352","author":"Singh","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jelectrocard.2016.12.004_bb0085","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/S0002-9149(01)01806-9","article-title":"Long-term efficacy and safety of propafenone and sotalol for the maintenance of sinus rhythm after conversion of recurrent symptomatic atrial fibrillation","volume":"88","author":"Bellandi","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jelectrocard.2016.12.004_bb0090","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1378\/chest.125.2.377","article-title":"Long-term maintenance of normal sinus rhythm in patients with current symptomatic atrial fibrillation: amiodarone vs propafenone, both in low doses","volume":"125","author":"Kochiadakis","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.jelectrocard.2016.12.004_bb0095","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1161\/01.CIR.101.10.1145","article-title":"Reversal of atrial electrical remodeling after cardioversion of persistent atrial fibrillation in humans","volume":"101","author":"Hobbs","year":"2000","journal-title":"Circulation"},{"issue":"47","key":"10.1016\/j.jelectrocard.2016.12.004_bb0100","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1093\/eurheartj\/ehu367","article-title":"Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation","volume":"35","author":"Cappato","year":"2014","journal-title":"Eur Heart J"}],"container-title":["Journal of Electrocardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022073616303302?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022073616303302?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T12:27:18Z","timestamp":1758284838000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022073616303302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S0022073616303302"],"URL":"https:\/\/doi.org\/10.1016\/j.jelectrocard.2016.12.004","relation":{},"ISSN":["0022-0736"],"issn-type":[{"value":"0022-0736","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Does antiarrhythmic drugs premedication improve electrical cardioversion success in persistent atrial fibrillation?","name":"articletitle","label":"Article Title"},{"value":"Journal of Electrocardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jelectrocard.2016.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}